Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation
By Ian Walker
Sandoz Group said that it has reached agreement with Amgen in the patent dispute over the company's denosumab biosimilars products, paving the way for it to launch its bone treatments Jubbonti and Wyost in the U.S. by May 31.
The Swiss pharmaceutical company didn't disclose any terms of the agreement but said it doesn't impact previously disclosed guidance for this year. It said on March 31 that the company expects 2024 net sales to grow mid-single digit in constant currencies.
Sandoz received U.S. Food and Drug Administration approval for Wyost and Jubbonti--the first denosumab biosimilars to treat skeletal-related events and osteoporosis--on March 5.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
April 30, 2024 02:02 ET (06:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk